Francisco Gomez-Dossi, MD
Neurology · Mishawaka, INNPI 1245287234
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Sanofi at 55.2% of the total. Reporting peaked in 2019 at $20,387 and has fallen 96.0% since, to $807 in 2025. Among neurology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $212.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$22K
- AbbVie$6K
- Argenx US, Inc.$6K
- Catalyst Pharmaceuticals, Inc.$4K
- Novartis$387
- AstraZeneca$320
- plus $2K from 35 others
Across 12 payments — averaging $2323.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$28K
What the payments were for
- Consulting fees$8,18820%
- Speaking & faculty fees$23,41358%
- Travel & lodging$4,15810%
- Food & beverage$4,37711%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUBAGIO$20,918
- UBRELVY$5,749
- DISEASE STATE$226
- SOLIRIS$150
How this compares
$40,154 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 29 | $419 |
| Gabapentin | 13 | $262 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $172 |
| Donepezil Hcl | 26 | $158 |
| Topiramate | 12 | $105 |
Paid to pharmacies, not to this prescriber.
Other neurology in Mishawaka
- Anitha RaoMishawaka$165K
- Paula Toth-RussellMishawaka$80K
- Michael EnglertMishawaka$50K
- Kevin KristlMishawaka$35K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.